Author: Li, Dongbo; Ji, Hongfei; Niu, Xingjian; Yin, Lei; Wang, Yiran; Gu, Yucui; Wang, Jinlu; Zhou, Xiaoping; Zhang, Han; Zhang, Qingyuan
Title: Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer Document date: 2019_12_19
ID: yj9mb88g_36
Snippet: Tumor-associated macrophages can adjust their phenotype and function in response to local cues provided by the TME. 49 Crosstalk between TAM and cancer cells is complex and involves exosomes, cytokines, and metabolites. [50] [51] [52] In the present study, we focused on the cytokine CCL2 secreted by macrophages and TA B L E 1 Univariate and multivariate analyses of clinicopathological features associated with PFS of patients with hormone receptor.....
Document: Tumor-associated macrophages can adjust their phenotype and function in response to local cues provided by the TME. 49 Crosstalk between TAM and cancer cells is complex and involves exosomes, cytokines, and metabolites. [50] [51] [52] In the present study, we focused on the cytokine CCL2 secreted by macrophages and TA B L E 1 Univariate and multivariate analyses of clinicopathological features associated with PFS of patients with hormone receptor-positive breast cancer examined its role in the endocrine resistance of breast cancer cells. We found that CCL2 activates the PI3K/Akt/mTOR pathway, which is a classical endocrine resistance pathway. However, the direct mechanism by which CCL2 activates this pathway was not determined. Another limitation of the present study was that due to the long culture time of drug-resistant cell lines, the effects of endocrine-resistant and -sensitive T47D cell lines on macrophages could not be repeated.
Search related documents:
Co phrase search for related documents- breast cancer and cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58
- breast cancer and clinicopathological feature: 1
- breast cancer and direct mechanism: 1
- breast cancer and endocrine resistance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- breast cancer and endocrine resistance pathway: 1, 2, 3, 4
- breast cancer and function phenotype: 1
- breast cancer and hormone receptor positive breast cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- breast cancer and hormone receptor positive breast cancer patient: 1
- breast cancer and multivariate univariate analysis: 1, 2, 3, 4
- breast cancer and pathway activate: 1
- breast cancer and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
- breast cancer and receptor positive breast cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
- breast cancer and tumor associate: 1
- breast cancer cell and cancer cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- breast cancer cell and cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- breast cancer cell and endocrine resistance: 1
- breast cancer cell and function phenotype: 1
- breast cancer cell and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- breast cancer cell and receptor positive breast cancer: 1
Co phrase search for related documents, hyperlinks ordered by date